Yesterday, it was announced that Turing Pharmaceuticals would lower the price of Dararprim from it's overnight price hike of 5400%, after a public backlash of global proportions.
When I first heard about the unethical,and yes I'll call it as I see it - dick move by Turing Pharmaceuticals CEO, Martin Shkreli, the man who decided to increase the price of the drug from $18 dollars a bottle to $750 dollars because he wanted to make more money from an older drug.
The hedge-funder turned Pharma owner felt that the 62 year old drug was undervalued -and stated he still felt that daraprim was undervalued after the price increase.
Watch his interview on Bloomberg TV interview and prepare to be disgusted.
Shkreli also used the skewed reasoning that the 5400% price increase would help generate funds for new cancer drugs that Turing Pharma hope to create and sell in the future.
Martin Shkreli has a history of Pharma greed and is current being sued by Rerophin, a Pharma company he founded and was eventually ousted from, because of allegations regarding misconduct, etc.
Like many, I was disgusted and angry when I heard about Daraprim - and as a person who relies on a a prescription drug in order to lived, I was scared.
In my mind I kept thinking: What if what was happening to Daraprim was happening to insulin? Like millions, I need insulin to live - and even with insurance - the cost of my monthly insulin is over almost four hundred dollars - and that price continues to go up.
If it wasn't for my Endo giving me generous amounts of insulin samples - I'd be royally screwed.
My fears don't seem so far fetched when you consider Shkreli's history of short selling Afrezza stock.
And of course I wasn’t the only one feeling that way, aI received tweets and Facebook messages of support. And 1 tweet from a person who told me that applying economic theory to something so personal was like a Doctor treating their spouse.Thought going through my mind continually: What if what w/happening w. #daraprim w/happening w/#insulin? #doc #diabetes #dayofdiabetes #hcsm— Kelly / Diabetes (@diabetesalish) September 22, 2015
But it is personal got me. VERY PERSONAL. And I think it's personal to every single person who has dealt with a chronic illness or a deadly disease.
But we don’t have to agree on everything -as long as we agree that that crazy Daraprim price hike was wrong.
"An old drug with multiple uses that help many," also reminded me of two other drugs used in the diabetes arena, Metformin and Ramipril.
Metformin, a generic diabetes medication (brand name, Glucophauge,) that was originally marketed to people with type 2 diabetes, but has since been used along with insulin to help prevent spikes and combat insulin resistance in people with type 1 diabetes.
Another magic power of Metformin is the protective effects it has on the vascular system - something that people with and without diabetes and regardless of the type, benefit from.
Ramipril, while not created as diabetes drug, is a generic ace-inhibitor (blood pressure medication,) that not only battles high blood pressure issues, (something people with diabetes are prone to,) but is also incredibly beneficial in protecting the kidneys of people with diabetes. Endo's prescribe ace inhibitors to many with diabetes and normal and high blood pressure in the hopes of preserving and protecting kidney function.
Both drugs have been on the market for years, both drugs are reasonably priced, and both drugs have multiple uses.
So yep, such an outrageous price increase could absolutely happen to drugs that people in the DOC and beyond use daily.
Then I thought of my diabetes heroes and saviors, Dr. Banting, Best and McCloud.
What would those men think of Shkeri's plan? Those men that all of us living with T1 diabetes owe our lives to.
Amazing men who not only discovered and patented their extract of insulin and won the Nobel Prize in the process, but decided to give that patent to the University of Toronto, who used the income generated from said patent to generate funding for diabetes research.
I had a feeling that those men were rolling over in their graves.
Then I saw the following tweet and became inspired and angry all over again.
Yesterday I saw this Meme at attn.com and originally attributed to imgur.com , comparing Shkeri to Jonas Salk, the Virologist/Redical Researcher extraordinaire who spent 7 years developing the polio vaccine. A man who felt that it was his moral duty to vaccinate the globe against polio - and who said that putting a patent on the vaccine would be like putting a patent on the sun.
And I'm the first one to say that I've benefited and that I'm alive because of pharmaceutical drugs and diabetes technology.
But like many Americans, the cost of living with a chronic disease keeps me up at night.
I worry about my financial future - I don't want pharma to be run by Shkreli's of the world
Except what Martin Shkreli attempted to do isn't new - It’s been happening with drugs for years, and the FDA needs to set up boundaries because if they don't, such hikes will continue. because people like Shekiri will buy the rights to old drugs and charge an astronomical price for them, all in the name of making a buck.
60 minutes did a story on the high cost of cancer drugs in October: http://www.cbsnews.com/news/cost-of-cancer-drugs-60-minutes-lesley-stahl-health-care/
And the price of generic drugs are skyrocketing so much, the feds are looking into it.
The Atlantic's Julie Beck wrote a disturbing and excellent piece on the Deraprim's exorbitant price hike being part of disturbing trend. CLICK HERE, and read it!
Beck's article quotes and links to a study that was recently published in Neurology.Org. The study states that first generation MS drugs, which originally cost between $8,000 and $11,00 dollars, now cost upwards of $60,000 a year for those who need them.
Click on the following to get a breakdown of the study - It's a must read that paints a very real and disturbing picture of drug pricing: http://www.neurology.org/content/early/2015/04/24/WNL.0000000000001608.full.pdf+html
Carolyn Johnson of the Washington Post said it best when she wrote: "Shkreli's actions were shocking for a simple reason: It was an unusual moment of complete transparancy in health care, where motive's prices, and how the system works are rarely ever talked about so nakedly."
Because of Shkreli's "nakedness" and his blatant greed, he allowed the public a peek into a very opaque system regarding drug pricing in the U.S., confirming our thoughts and fears in the process - And I thank him for that.
Now that our fears are confirmed - we must stop the epidemic of The Daraprim Effect from become a plague - because our health and our financial futures depend on it.